摘要
包括白血病,淋巴瘤和骨髓瘤在内的血液系统恶性肿瘤造成的死亡人数占癌症死亡总人数的10%。如今,人们通过研究血液系统恶性肿瘤并根据形态学特征,细胞表面标记物,遗传信息畸变和分子标记物对其进行分类。不幸的是,大部分情况下,设立的标准并不满足早期诊断和完全分类。后一个问题阻碍了病人治疗方案优选,导致经常出现各种各样的临川治疗表现和反应。这种多样性证明了人们需要改良的分析方法,新的诊断标记物以及这些肿瘤的分类。非编码RNA是许多生物过程的主要调节器,包括表观遗传响应 ,细胞凋亡和细胞周期。癌症研究最近进展导致遗传信息在临床使用上的展开。事实上,许多实验正在研究miRNAs和lncRNAs在造血分化和增殖以及许多血液系统恶性肿瘤中的突出作用。这些研究主要目的在于发现减少正常组织出现副作用的新的治疗可能性。此外,同样重要的是,ncRNAs与临床特征的联系引起了越来越多的人的关注。这篇综述主要研究血液癌症常见形式中反常的ncRNAs表达与正常组相比,每一种形式都有独特的特征。除了它们的基础功能,由于众所周知的ncRNAs能调整信号和通路网络,在此,我们讨论了miRNAs和lncRNAs成为有效诊断新强大靶点的可能性和血液系统恶性肿瘤病人的预测反应。
关键词: 非编码RNAs,微RNAs,长非编码RNAs,多发性骨髓瘤,非霍奇金淋巴瘤 ,霍奇金淋巴瘤 ,白血病,诊断,判病结局,治疗,生物标记物
Current Drug Targets
Title:Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment
Volume: 18 Issue: 1
Author(s): Gabriella Misso, Mayra Rachele Zarone, Anna Grimaldi, Maria Teresa Di Martino, Angela Lombardi, Hiromichi Kawasaki, Paola Stiuso and Pierfrancesco Tassone, Pierosandro Tagliaferri, Michele Caraglia
Affiliation:
关键词: 非编码RNAs,微RNAs,长非编码RNAs,多发性骨髓瘤,非霍奇金淋巴瘤 ,霍奇金淋巴瘤 ,白血病,诊断,判病结局,治疗,生物标记物
摘要: Hematological malignancies, accounting for about 10% of all deaths for cancer, include various forms of leukemia, lymphoma and myeloma. At present, hematological malignancies are analyzed and classified on the basis of morphologic characteristics, cell surface markers, cytogenetic aberrations and molecular markers. Unfortunately, in most cases, standard criteria are not sufficient for both an early diagnosis and a complete classification. The latter issue hampers an optimal therapeutic choice for these patients that often display heterogeneous clinical outcomes or responses to therapy. This heterogeneity has determined a need for improved methods of analysis and novel markers for diagnosis and classification of these malignancies. Non coding RNAs act as master regulators of numerous biological processes including epigenetic response, apoptosis and cell cycle. The recent advances in cancer research have led to a spreading out in the clinical use of genomic information; in fact, several studies are investigating the prominent role of both miRNAs and lncRNAs in hematopoietic differentiation and proliferation, as well as in the development of various hematological malignancies. These investigations are mainly aimed at researching new therapeutic opportunities that could boost a reduced risk of adverse events in normal tissues. Moreover, not less important, there is also a growing interest in determining how ncRNAs are associated with clinical features. In this review we focus on the aberrant ncRNAs expression in the most common forms of blood cancers, each of which exhibits a unique signature in comparison to normal counterparts. In addition to their regulatory role and in virtue of the well known ncRNAs' capacity of modulating signal and pathway networks, herein we discuss both miRNAs' and lncRNAs' potential as new powerful biomarkers for efficient diagnosis and prediction of response for patients with hematological malignancies.
Export Options
About this article
Cite this article as:
Gabriella Misso, Mayra Rachele Zarone, Anna Grimaldi, Maria Teresa Di Martino, Angela Lombardi, Hiromichi Kawasaki, Paola Stiuso and Pierfrancesco Tassone, Pierosandro Tagliaferri, Michele Caraglia , Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment, Current Drug Targets 2017; 18 (1) . https://dx.doi.org/10.2174/1389450117666160606104208
DOI https://dx.doi.org/10.2174/1389450117666160606104208 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Seeking the 5th Base of DNA Using Chromatographic Methods of Analysis
Current Organic Chemistry Mechanism of Anti-Tumor Effect by Curcumin in Hematological Malignancies
Current Pharmaceutical Analysis Editorial (Thematic Issue: Targeting Epithelial-to-Mesenchymal Transition for Cancer Therapy)
Current Pharmaceutical Design The Role of Soluble 5'-Nucleotidases in the Conversion of Nucleotide Analogs: Metabolic and Therapeutic Aspects
Current Medicinal Chemistry Meet Our Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery Maprotiline Prompts an Antitumour Effect by Inhibiting PD-L1 Expression in Mice with Melanoma
Current Molecular Pharmacology Toll-Like Receptors in Alzheimer's Disease: A Therapeutic Perspective
CNS & Neurological Disorders - Drug Targets Epigenetic Modifications in Acute Lymphoblastic Leukemia: From Cellular Mechanisms to Therapeutics
Current Gene Therapy Metronomic Therapy for Multi Relapsed/Refractory Lymphoma. A Pilot Study
Current Angiogenesis (Discontinued) The Functions of Histone Modification Enzymes in Cancer
Current Protein & Peptide Science LncRNA HOTAIR as Prognostic Circulating Marker and Potential Therapeutic Target in Patients with Tumor Diseases
Current Drug Targets In Vitro and In Vivo Sirolimus for Modulation of Allogeneic Hematopoietic Stem Cell Transplantation
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Cancer Stem-Cells Patents in the Context of their Therapeutic Purposes: Exploring the Latest Trends (2011-2015)
Recent Patents on Regenerative Medicine Discovery of Small Molecules that Target Autophagy for Cancer Treatment
Current Medicinal Chemistry Reversal of Tumor Induced Dendritic Cell Paralysis: A Treatment Regimen Against Cancer
Current Immunology Reviews (Discontinued) MicroRNA in Multiple Myeloma - A Role in Pathogenesis and Prognostic Significance
Current Medicinal Chemistry Targeting Molecular Imaging of Breast Cancer by Radioimmunodetection Method in Nuclear Medicine
Current Molecular Imaging (Discontinued) Integrin Function and Signaling as Pharmacological Targets in Cardiovascular Diseases and in Cancer
Current Pharmaceutical Design Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment
Current Pharmaceutical Design Targeting the NF-κB pathway in prostate cancer: a promising therapeutic approach?
Current Drug Targets